INCA033989 inhibits abnormal TPOR signaling in mutCALR-expressing MPN cells without affecting normal hematopoiesis [117], validating its therapeutic potential as a targeted therapy for MPN that does not interfere with normal hematopoiesis. This evidence concerns the gene MPL and myeloproliferative disorder.